SCHEMBL6700334

SCHEMBL6700334

COc1ccc(CC#Cc2cc3c(o2)N(C)C(=O)N(Cc2ccc(F)c(F)c2)C3)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCB1 P08183 1/20 0.36
ABCC1 P33527 1/20 0.36
ABCG2 Q9UNQ0 1/20 0.36
HTR1A P08908 2/20 0.34
HTR7 P34969 2/20 0.34
HTR6 P50406 2/20 0.34
CYP3A4 P08684 1/20 0.33
DPP4 P27487 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33
ALDH1A1 P00352 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
P2RX7 Q99572 1/20 0.33
CMA1 P23946 1/20 0.32
GRM2 Q14416 1/20 0.32
GAA P10253 1/20 0.32
MAPK1 P28482 1/20 0.32
ANO1 Q5XXA6 1/20 0.32
PKM P14618 1/20 0.32
FGFR1 P11362 1/20 0.32
FGFR2 P21802 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6702121 0.81 ABCB1 (0.34) ABCB1ABCC1ABCG2CYP3A4DPP4
SCHEMBL6699545 0.80 MMP13 (0.39) ALDH1A1SMN1; SMN2GRM2PKMTHRB
SCHEMBL6704262 0.76 P2RX7 (0.36) HDAC6P2RX7MAPK1
SCHEMBL6699350 0.76 P2RX7 (0.35) CYP3A4DPP4P2RX7GAAMAPK1
SCHEMBL6694967 0.74 MMP13 (0.46) HDAC6ALDH1A1POLB
SCHEMBL6697984 0.74 ALDH1A1 (0.36) ALDH1A1MAPK1
SCHEMBL6814225 0.74 P2RX7 (0.35) ALDH1A1P2RX7MAPK1PKM
SCHEMBL6698004 0.72 MAPT (0.41) ALDH1A1MAPK1PKMTHRBPOLB
SCHEMBL6706967 0.70 MMP13 (0.38)
SCHEMBL6700612 0.70 MAPK1 (0.31) HTR6ALDH1A1MAPK1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040038994-A1 Pyrimidine fused bicyclic metalloproteinase inhibitors WILSON MICHAEL WILLIAM (US) 2004-02-26 US claimed
US-20040038994-A1 Pyrimidine fused bicyclic metalloproteinase inhibitors WILSON MICHAEL WILLIAM (US) 2004-02-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040038994-A1 Pyrimidine fused bicyclic metalloproteinase inhibitors MMP9, MMP1, MMP2 ABCB1 540/4885ABCC1 642/4885ABCG2 1050/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.